Police & Firemen s Retirement System of New Jersey Sells 2,429 Shares of DaVita Inc. $DVA

Police & Firemen s Retirement System of New Jersey cut its stake in DaVita Inc. (NYSE:DVA) by 14.2% in the second quarter, HoldingsChannel reports. The institutional investor owned 14,634 shares of the company’s stock after selling 2,429 shares during the quarter. Police & Firemen s Retirement System of New Jersey’s holdings in DaVita were worth $2,085,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of DVA. Invesco Ltd. increased its position in shares of DaVita by 3.4% during the 1st quarter. Invesco Ltd. now owns 1,642,947 shares of the company’s stock worth $251,322,000 after purchasing an additional 53,402 shares in the last quarter. Northern Trust Corp grew its stake in DaVita by 20.2% during the first quarter. Northern Trust Corp now owns 890,632 shares of the company’s stock worth $136,240,000 after buying an additional 149,858 shares during the last quarter. Gates Capital Management Inc. increased its holdings in shares of DaVita by 0.7% during the first quarter. Gates Capital Management Inc. now owns 722,205 shares of the company’s stock worth $110,476,000 after buying an additional 4,698 shares in the last quarter. Amundi raised its stake in shares of DaVita by 16.0% in the first quarter. Amundi now owns 517,690 shares of the company’s stock valued at $79,584,000 after acquiring an additional 71,304 shares during the last quarter. Finally, Epoch Investment Partners Inc. boosted its holdings in shares of DaVita by 10.7% in the 1st quarter. Epoch Investment Partners Inc. now owns 407,921 shares of the company’s stock worth $62,400,000 after acquiring an additional 39,485 shares in the last quarter. 90.12% of the stock is currently owned by institutional investors.

DaVita Stock Down 1.0%

Shares of DVA stock opened at $115.40 on Thursday. The firm has a market cap of $8.15 billion, a price-to-earnings ratio of 11.88, a PEG ratio of 0.91 and a beta of 1.13. DaVita Inc. has a 12 month low of $113.97 and a 12 month high of $179.60. The stock has a 50-day moving average price of $126.60 and a 200 day moving average price of $134.86.

DaVita (NYSE:DVA) last issued its earnings results on Wednesday, October 29th. The company reported $2.51 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.17 by ($0.66). DaVita had a net margin of 5.80% and a return on equity of 815.62%. The business had revenue of $3.42 billion during the quarter, compared to the consensus estimate of $3.43 billion. During the same period last year, the business posted $2.59 EPS. The firm’s revenue for the quarter was up 4.8% compared to the same quarter last year. DaVita has set its FY 2025 guidance at 10.350-11.150 EPS. Sell-side analysts predict that DaVita Inc. will post 10.76 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on DVA shares. Cowen reaffirmed a “hold” rating on shares of DaVita in a report on Monday, November 3rd. Truist Financial set a $140.00 target price on DaVita in a report on Tuesday, October 14th. Zacks Research cut DaVita from a “hold” rating to a “strong sell” rating in a report on Thursday, October 30th. Weiss Ratings reiterated a “hold (c)” rating on shares of DaVita in a research report on Thursday, November 13th. Finally, Bank of America lowered their price objective on shares of DaVita from $145.00 to $140.00 and set an “underperform” rating for the company in a research report on Wednesday, September 10th. Five analysts have rated the stock with a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Reduce” and a consensus price target of $148.00.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.